Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.56 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Myrophine SCHEMBL26043 | 1.00 | OPRD1 (0.56) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL3477477 | 0.89 | OPRM1 (0.71) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL7775794 | 0.89 | OPRM1 (0.71) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL7770909 | 0.89 | OPRM1 (0.71) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL3477727 | 0.86 | OPRM1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL29610430 | 0.85 | OPRM1 (0.77) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL22959877 | 0.85 | OPRM1 (0.77) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL3477203 | 0.84 | OPRM1 (0.70) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL8208039 | 0.83 | OPRM1 (0.62) | OPRD1OPRM1OPRK1 | |
| SCHEMBL19463540 | 0.83 | OPRD1 (0.72) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3064199-B1 | ABUSE-DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | BUZZZ PHARMACEUTICALS LTD (IE) | 2023-12-20 | — | — | EP | claimed |
| EP-3313407-B1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2023-07-19 | — | — | EP | claimed |
| EP-3385252-B1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| CN-113939277-B | Formulations and methods for drug infusion into the bladder and treatment of bladder diseases | 特瑞纲制药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117295508-A | Opioid dosage reduction compositions and methods of use thereof | 迈索布拉斯特国际有限公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-1765303-B2 | ORAL TABLET SAFEGUARDED AGAINST ABUSE | GRUENENTHAL GMBH (DE) | 2022-11-23 | — | — | EP | disclosed |